-
Journal of Controlled Release :... Nov 2010
Topics: Administration, Cutaneous; Animals; Drug Delivery Systems; Lasers; Prednisone; Skin; Swine
PubMed: 21529638
DOI: 10.1016/j.jconrel.2010.07.032 -
Experimental Physiology Sep 2023What is the topic of this review? The contribution of gut microbial signalling to skeletal muscle maintenance and development and identification of potential therapeutic... (Review)
Review
NEW FINDINGS
What is the topic of this review? The contribution of gut microbial signalling to skeletal muscle maintenance and development and identification of potential therapeutic targets in progressive muscle degenerative diseases such as Duchenne muscular dystrophy. What advances does it highlight? Gut microbe-derived metabolites are multifaceted signalling molecules key to muscle function, modifying pathways contributing to skeletal muscle wasting, making them a plausible target for adjunctive therapy in muscular dystrophy.
ABSTRACT
Skeletal muscle is the largest metabolic organ making up ∼50% of body mass. Because skeletal muscle has both metabolic and endocrine properties, it can manipulate the microbial populations within the gut. In return, microbes exert considerable influence on skeletal muscle via numerous signalling pathways. Gut bacteria produce metabolites (i.e., short chain fatty acids, secondary bile acids and neurotransmitter substrates) that act as fuel sources and modulators of inflammation, influencing host muscle development, growth and maintenance. The reciprocal interactions between microbes, metabolites and muscle establish a bidirectional gut-muscle axis. The muscular dystrophies constitute a broad range of disorders with varying disabilities. In the profoundly debilitating monogenic disorder Duchenne muscular dystrophy (DMD), skeletal muscle undergoes a reduction in muscle regenerative capacity leading to progressive muscle wasting, resulting in fibrotic remodelling and adipose infiltration. The loss of respiratory muscle in DMD culminates in respiratory insufficiency and eventually premature death. The pathways contributing to aberrant muscle remodelling are potentially modulated by gut microbial metabolites, thus making them plausible targets for pre- and probiotic supplementation. Prednisone, the gold standard therapy for DMD, drives gut dysbiosis, inducing a pro-inflammatory phenotype and leaky gut barrier contributing to several of the well-known side effects associated with chronic glucocorticoid treatment. Several studies have observed that gut microbial supplementation or transplantation exerts positive effects on muscle, including mitigating the side effects of prednisone. There is growing evidence in support of the potential for an adjunctive microbiota-directed regimen designed to optimise gut-muscle axis signalling, which could alleviate muscle wasting in DMD.
Topics: Animals; Mice; Muscular Dystrophy, Duchenne; Prednisone; Muscle, Skeletal; Glucocorticoids; Inflammation; Mice, Inbred mdx
PubMed: 37269541
DOI: 10.1113/EP091063 -
Fertility and Sterility Oct 1979A group of 106 women of reproductive age with laboratory and clinical evidence of hyperandrogenism was treated with prednisone. The daily dosage varied between 7.5 and...
A group of 106 women of reproductive age with laboratory and clinical evidence of hyperandrogenism was treated with prednisone. The daily dosage varied between 7.5 and 10 mg. Ovulatory activity was assessed prior to and during therapy by basal body temperature and observation of changes in the cervical os and cervical mucus. Plasma testosterone levels were significantly suppressed by prednisone therapy. This was associated with initiation of ovulatory activity in 5 of 14 (35.7%) amenorrheic patients and 10 of 11 (90.9%) anovulatory patients. In 81 ovulatory patients, prednisone therapy resulted in statistically significant shortening of the follicular phase and lengthening of the luteal phase of the menstrual cycle. The mean length of the menstrual cycle was unchanged. Significant correlations between percentage suppression of plasma testosterone and shortening of the follicular phase or lengthening of the luteal phase were observed. Suppression of plasma testosterone by prednisone was maximal after 2 months of treatment, while the effect on the phases of the menstrual cycle was progressive with duration of treatment. The effects of prednisone at daily dosages of 7.5 or 10 mg were not significantly different. These results suggest that prednisone therapy in hyperandrogenic women exerts an effect on both phases of the menstrual cycle, possibly related to suppression of plasma testosterone levels.
Topics: Adult; Endocrine System Diseases; Female; Humans; Menstruation; Prednisone; Testosterone
PubMed: 488427
DOI: 10.1016/s0015-0282(16)44296-2 -
Nederlands Tijdschrift Voor Geneeskunde May 1996
Review
Topics: Anti-Inflammatory Agents; Child; Humans; Male; Muscular Dystrophies; Prednisone
PubMed: 8692335
DOI: No ID Found -
Nederlands Tijdschrift Voor Geneeskunde Sep 1974
Review
Topics: Azathioprine; Cyclophosphamide; Humans; Lupus Erythematosus, Systemic; Nephritis; Prednisone
PubMed: 4606008
DOI: No ID Found -
The New England Journal of Medicine Dec 1979
Topics: Adrenal Cortex Hormones; Adult; Child; Glomerulonephritis; Humans; Nephrotic Syndrome; Prednisone; Remission, Spontaneous; Time Factors; Uremia
PubMed: 503152
DOI: 10.1056/NEJM197912133012408 -
Annals of Internal Medicine Jun 1979
Topics: Crohn Disease; Drug Evaluation; Humans; Prednisone
PubMed: 443697
DOI: 10.7326/0003-4819-90-6-983 -
Deutsche Medizinische Wochenschrift... Sep 1991
Topics: Administration, Oral; Asthma; Humans; Prednisone; Recurrence
PubMed: 1884680
DOI: No ID Found -
The Medical Letter on Drugs and... Dec 1971
Comparative Study
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Costs and Cost Analysis; Humans; Hypersensitivity; Prednisone; Sodium
PubMed: 5163919
DOI: No ID Found -
The Medical Letter on Drugs and... Nov 1975
Topics: Administration, Oral; Adrenal Cortex Hormones; Biological Availability; Humans; Prednisone
PubMed: 1196257
DOI: No ID Found